Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement

8 Nov 2024

Abstract excerpt

BACKGROUND: Wild-type and hereditary transthyretin-mediated amyloidosis (ATTRwt and ATTRv amyloidosis, respectively) are progressive, fatal diseases with a broad range of clinical presentations and multisystem effects. Despite having a higher prevalence, ATTRwt amyloidosis is less well characterized due to its non-hereditary nature, and its relatively poorer disease awareness delays diagnosis. Understanding of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloidosis: Diagnosis, Treatment, Outcomes
Share to Dermatological and Skeletal Disorders
Share to IgG4-Related and Inflammatory Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39516862
DOI: 10.1186/s13023-024-03407-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvementPMID 39516862Read ↗

Clinical Practice and Diagnostic Trends in Hereditary Transthyretin Amyloidosis: A 25-Year Observational Study.Semantic proximity Read ↗

Guideline of transthyretin-related hereditary amyloidosis for cliniciansSemantic proximity Read ↗

Expert opinion on monitoring symptomatic hereditary transthyretin-mediated amyloidosis and assessment of disease progressionSemantic proximity Read ↗

Not So Rare After All: Rethinking Hereditary Transthyretin AmyloidosisSemantic proximity Read ↗

Patient and family experience with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) and Polyneuropathy (ATTR-PN) Amyloidosis: Results of two focus groupsSemantic proximity Read ↗

Clinical and genetic profile of patients enrolled in the Transthyretin Amyloidosis Outcomes Survey (THAOS): 14-year update.Semantic proximity Read ↗

Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in France.Semantic proximity Read ↗

Cardiac amyloidosis: the great pretender.Semantic proximity Read ↗

Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy ManagementSemantic proximity Read ↗

Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial.Semantic proximity Read ↗

A description of variant transthyretin amyloidosis (ATTRv) stage 1 patients and asymptomatic carriers in Spain: the EMPATIa study.Semantic proximity Read ↗

Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UKSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.